Cryoablation System Shows 83.9% Recurrence-Free Rate in Kidney Cancer Trial
The ProSense Cryoablation System achieved an 83.9% recurrence-free rate in kidney cancer patients after 4 years in the ICESECRET trial. The system treats small renal masses up to 5 cm and is approved in multiple global markets. Detailed results will be presented at the European Conference on Interventional Oncology in April 2026.